Search Results - "HUSE, SAMUEL"

  • Showing 1 - 13 results of 13
Refine Results
  1. 1

    Comparative Safety and Effectiveness of Sotalol Versus Dronedarone After Catheter Ablation for Atrial Fibrillation by Wharton, John Marcus, Piccini, Jonathan P, Koren, Andrew, Huse, Samuel, Ronk, Christopher J

    Published in Journal of the American Heart Association (01-02-2022)
    “…Background Atrial tachyarrhythmias are common after atrial fibrillation ablation, so adjunctive antiarrhythmic drug therapy is often used. Data on the…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Prevalence of STK11, KEAP1, and KRAS mutations/co-mutations and associated clinical outcomes for patients newly diagnosed with metastatic non-small cell lung cancer by Dabbous, Firas, Wang, Ching-Yu, Simmons, Daniel, Huse, Samuel, Jassim, Rami

    Published in Journal of clinical oncology (01-06-2023)
    “…e21186 Background: Data on the prevalence of emerging mutations /co-mutations (e.g., STK11, KRAS, and KEAP1) and associated clinical outcomes in metastatic…”
    Get full text
    Journal Article
  4. 4

    Abstract 13528: Sex Differences in Healthcare Resource Utilization in Patients With Atrial Fibrillation Receiving Dronedarone versus Sotalol Following Ablation by Zeitler, Emily P, Stein, Dara, PREBLICK, RON, Kabadi, Shaum, MCKINDLEY, David, Rashkin, Jason, Huse, Samuel, Stamas, Nicole, Kim, Michael H

    Published in Circulation (New York, N.Y.) (08-11-2022)
    “…IntroductionPatterns of anti-arrhythmic drug therapy for atrial fibrillation (AF) treatment and outcomes may differ by sex. Dronedarone has shown clinical…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7

    Abstract 13500: Real-World Healthcare Resource Utilization Outcomes With Dronedarone versus Sotalol Following Ablation in Adults With Atrial Fibrillation by Zeitler, Emily P, Stein, Dara, PREBLICK, RON, Kabadi, Shaum M, MCKINDLEY, David, Rashkin, Jason, Huse, Samuel, Stamas, Nicole, Kim, Michael H

    Published in Circulation (New York, N.Y.) (08-11-2022)
    “…IntroductionDronedarone has shown clinical benefit vs sotalol in adults with atrial fibrillation (AF) post-ablation, but healthcare resource utilization (HCRU)…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Economic Burden of Infections Following Allogeneic Hematopoietic Cell Transplant for Hematologic Malignancies by Berger, Ariel, Grubb, Walter W, Huse, Samuel, Mohanty, Maitreyee, Ferraro, John, Daniels, Moya, Levin, Wendy J.

    Published in Blood (03-12-2015)
    “…Background: Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative option for many hematologic malignancies, but is associated with…”
    Get full text
    Journal Article
  10. 10

    Economic Burden of Acute Graft-Versus-Host Disease (GvHD) Following Allogeneic Hematopoietic Cell Transplant (HCT) for Hematologic Malignancies by Grubb, Walter W, Huse, Samuel, Alam, Naufil, Dychter, Samuel, Wingard, John R., Majhail, Navneet S., Berger, Ariel

    Published in Blood (02-12-2016)
    “…Background: Allogeneic HCT is a potentially curative procedure for many hematologic malignancies, but is associated with several complications. Acute GvHD is a…”
    Get full text
    Journal Article
  11. 11

    Economic burden of relapsed or refractory multiple myeloma: Results from an international trial by Robinson, Don, Orlowski, Robert Z., Stokes, Michael, He, Jianming, Huse, Samuel, Chitnis, Abhishek, Kranenburg, Britte, Lam, Annette

    Published in European journal of haematology (01-08-2017)
    “…Objective The direct cost of relapsed or refractory multiple myeloma (RRMM) is documented; indirect costs are being explored. Healthcare payers seek…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Replication of Mini-Sentinel Study Assessing Mirabegron and Cardiovascular Risk in Non-Mini-Sentinel Databases by Simeone, Jason C., Nordstrom, Beth L., Appenteng, Kwame, Huse, Samuel, D’Silva, Milbhor

    Published in Drugs -- real world outcomes (01-03-2018)
    “…Background In 2014, the US Food and Drug Administration (FDA) initiated a prospective routine surveillance using the Mini-Sentinel (M-S) program to assess…”
    Get full text
    Journal Article